MEDJ
Tuesday October 12, 11:30 am Eastern Time
Company Press Release
SOURCE: Medi-Ject Corp.
Medi-Ject Corporation Announces Asian Device
Approvals and First Product Shipment to SciGen
Medi-Ject Expands its Asian Presence Beyond Japan and Begins Shipments Of Needle-Free
Injectors for Human Growth Hormone to Additional Markets In Southeast Asia
MINNEAPOLIS, Oct. 12 /PRNewswire/ -- Medi-Ject Corporation (Nasdaq: MEDJ - news) today announced that one of its
pharmaceutical partners, SciGen Pte Ltd of Singapore, has received government approvals to market a Medi-Ject needle-free
injector, the SciTojet, for human growth hormone injections in several southeast Asian markets, including Hong Kong, The
Philippines, Singapore and Malaysia. As a result of these approvals, Medi-Ject Corporation announced the first shipment of
SciTojet injectors to SciGen Pte Ltd.
''Asia is a large and attractive market opportunity for our growth hormone needle-free injectors,'' said Dr. Franklin Pass,
Chairman and CEO of Medi-Ject. ''We have already had good success in Japan, where our growth hormone injector has been
very well accepted by children and their parents. In Asia, we hope to duplicate the market penetration we have begun to
achieve in Europe. The basis for our success in these markets is that our growth hormone injector fills an important market
need: independent studies show that the daily administration of growth hormone without a needle is preferred over needle
alternatives, especially among children.''
Any statements released by Medi-Ject that are forward looking, including statements relating to future product development,
product sales, development and licensing agreements, and research activities, are made pursuant to the Safe Harbor provisions
of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward looking statements involve risks
and uncertainties which may affect the Company's business and prospects, including changes in economic and market
conditions, healthcare legislation, progress in Medi-Ject's alliances with pharmaceutical companies, the development of
competing drug delivery systems, management of growth and other factors discussed in the Company's filings with the
Securities and Exchange Commission.
Medi-Ject Corporation is the world's leading developer and marketer of needle-free drug delivery systems. The Company
manufactures hand-held injectors that deposit pharmaceuticals, including insulin and growth hormone, under the skin without a
needle. Presently, these needle-free injection systems are distributed in over twenty countries. Headquartered in Minneapolis,
the Company's common stock is traded on the Nasdaq Small Cap Market under the symbol MEDJ.
Company information can be found on the Internet under Medi-Ject's site on the World Wide Web at
mediject.com . For more information on Medi-Ject Corporation via facsimile at no additional cost, simply dial
1-800-PRO-INFO and enter company's ticker symbol MEDJ.
SOURCE: Medi-Ject Corp.
More Quotes and News:
Medi-Ject Corp (NasdaqSC:MEDJ - news)
Related News Categories: medical/pharmaceutical
|
